U.S. Life Sciences Industry Analysis
UpdatedJun 30, 2024
DataAggregated Company Financials
Companies62
- 7D-2.0%
- 3M-8.0%
- 1Y-2.1%
- YTD-2.9%
Over the last 7 days, the Life Sciences industry has dropped 2.0%, driven by declines in Thermo Fisher Scientific and Danaher of 2.1% and 2.0%, respectively. In contrast, Tempus AI has gained 22%. As for the longer term, the industry's performance has been flat for the past year. Earnings are forecast to grow by 16% annually.
Industry Valuation and Performance
Has the U.S. Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Sun, 30 Jun 2024 | US$680.5b | US$141.3b | US$12.2b | 37.9x | 55.9x | 4.8x |
| Tue, 28 May 2024 | US$726.8b | US$141.5b | US$12.4b | 38.7x | 58.5x | 5.1x |
| Thu, 25 Apr 2024 | US$721.5b | US$141.6b | US$12.7b | 41.7x | 56.7x | 5.1x |
| Sat, 23 Mar 2024 | US$749.2b | US$142.1b | US$12.8b | 44.7x | 58.4x | 5.3x |
| Mon, 19 Feb 2024 | US$720.7b | US$142.2b | US$12.5b | 43.3x | 57.5x | 5.1x |
| Wed, 17 Jan 2024 | US$684.9b | US$153.8b | US$14.2b | 35.2x | 48.3x | 4.5x |
| Fri, 15 Dec 2023 | US$679.9b | US$153.8b | US$14.2b | 37.7x | 47.7x | 4.4x |
| Sun, 12 Nov 2023 | US$585.3b | US$153.8b | US$14.0b | 30.9x | 41.9x | 3.8x |
| Tue, 10 Oct 2023 | US$645.4b | US$154.6b | US$11.2b | 33.3x | 57.6x | 4.2x |
| Thu, 07 Sep 2023 | US$710.8b | US$154.6b | US$11.2b | 31.8x | 63.4x | 4.6x |
| Sat, 05 Aug 2023 | US$724.6b | US$154.7b | US$11.3b | 30.2x | 64.4x | 4.7x |
| Mon, 03 Jul 2023 | US$697.8b | US$152.4b | US$12.5b | 29.5x | 55.8x | 4.6x |
| Wed, 31 May 2023 | US$668.8b | US$152.2b | US$12.5b | 27.4x | 53.5x | 4.4x |
| Fri, 28 Apr 2023 | US$684.6b | US$152.9b | US$9.6b | 29x | 71.6x | 4.5x |
| Sun, 26 Mar 2023 | US$705.3b | US$154.5b | US$10.8b | 26.1x | 65.2x | 4.6x |
| Tue, 21 Feb 2023 | US$744.5b | US$154.2b | US$10.9b | 31.7x | 68x | 4.8x |
| Thu, 19 Jan 2023 | US$757.7b | US$155.3b | US$8.5b | 30.8x | 88.9x | 4.9x |
| Sat, 17 Dec 2022 | US$742.7b | US$155.2b | US$8.8b | 28.5x | 84.6x | 4.8x |
| Mon, 14 Nov 2022 | US$775.5b | US$154.9b | US$8.8b | 28.5x | 87.9x | 5x |
| Wed, 12 Oct 2022 | US$699.8b | US$152.5b | US$17.0b | 23.5x | 41.1x | 4.6x |
| Fri, 09 Sep 2022 | US$792.8b | US$152.3b | US$17.3b | 30.3x | 45.8x | 5.2x |
| Sun, 07 Aug 2022 | US$830.5b | US$151.9b | US$18.2b | 33.6x | 45.6x | 5.5x |
| Tue, 05 Jul 2022 | US$730.5b | US$148.1b | US$20.1b | 30.3x | 36.3x | 4.9x |
| Thu, 02 Jun 2022 | US$744.1b | US$148.1b | US$20.1b | 30.6x | 37x | 5x |
| Sat, 30 Apr 2022 | US$777.1b | US$150.7b | US$21.1b | 31.6x | 36.9x | 5.2x |
| Mon, 28 Mar 2022 | US$857.5b | US$146.0b | US$25.4b | 35.8x | 33.8x | 5.9x |
| Wed, 23 Feb 2022 | US$820.2b | US$144.8b | US$25.4b | 37.5x | 32.3x | 5.7x |
| Fri, 21 Jan 2022 | US$850.1b | US$138.0b | US$27.3b | 38.3x | 31.1x | 6.2x |
| Sun, 19 Dec 2021 | US$964.3b | US$138.0b | US$27.3b | 44.7x | 35.3x | 7x |
| Tue, 16 Nov 2021 | US$956.4b | US$137.8b | US$27.1b | 46.2x | 35.3x | 6.9x |
| Thu, 14 Oct 2021 | US$701.6b | US$106.0b | US$18.5b | 45.6x | 37.8x | 6.6x |
| Sat, 11 Sep 2021 | US$749.6b | US$106.0b | US$18.6b | 48.9x | 40.3x | 7.1x |
| Mon, 09 Aug 2021 | US$714.8b | US$105.8b | US$18.7b | 47.9x | 38.3x | 6.8x |
Price to Earnings Ratio
37.2x
Current Industry PE
- Investors are optimistic on the American Life Sciences industry, and appear confident in long term growth rates.
- The industry is trading at a PE ratio of 55.9x which is higher than its 3-year average PE of 51.6x.
- The industry is trading close to its 3-year average PS ratio of 5.2x.
Past Earnings Growth
- The earnings for companies in the Life Sciences industry have declined 12% per year over the last three years.
- Meanwhile revenues for these companies have grown 12% per year.
- This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.
Industry Trends
Which industries have driven the changes within the U.S. Healthcare industry?
| US Market | 0.074% | |
| Healthcare | -0.34% | |
| Life Sciences | -2.02% | |
| Clinical Research and Equipment | -2.02% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| TEM Tempus AI | US$35.00 | 22.2% +US$1.0b | n/a | PS10.3x | |
| MEDP Medpace Holdings | US$411.85 | 1.9% +US$241.7m | 71.5% | PE40.8x | |
| STVN Stevanato Group | US$18.34 | 3.1% +US$150.0m | -43.4% | PE34.3x | |
| ADPT Adaptive Biotechnologies | US$3.62 | 11.7% +US$56.0m | -46.1% | PS3.1x | |
| RGEN Repligen | US$126.06 | 0.6% +US$41.3m | -10.9% | PE474.6x |
